-
卵巢癌的发病率在妇科恶性肿瘤中位居第一。由于多数患者在其发现时多属晚期, 导致卵巢癌患者的病死率一直居高不下, 5年生存率仅为30%左右。同其他肿瘤一样, 卵巢癌的复发是影响卵巢癌患者预后的主要因素之一[1]。PET具有优越的功能成像技术, 目前PET检查主要是以18F-FDG为示踪剂。PET-CT在卵巢癌的分期、远处转移灶显示、放化疗疗效检测、术后复发转移等方面的临床价值尤为显著。为了解PET-CT在探测和诊断卵巢癌术后复发、转移灶中的价值, 笔者对行PET-CT检查的65例卵巢癌原发灶患者进行了回顾性分析, 现报道如下。
18F-FDG PET-CT在探测卵巢癌术后复发与转移中的应用价值
18F-FDG PET-CT imaging in the detection of recurrent and metastasis ovarian cancer
-
摘要:
目的 探讨18F-FDG PET-CT在探测和诊断卵巢癌术后复发、转移中的应用价值。 方法 回顾性分析65例卵巢癌术后患者的全身PET-CT结果。临床随访时间为3~57个月。确诊卵巢癌是否复发或转移的依据为手术病理学检查、多种影像学检查和临床随访。 结果 65例患者中, 55例有肿瘤复发、转移, 10例无肿瘤复发。65例卵巢癌患者中, PET-CT图像共显示阳性灶180个, 最后经手术病理或临床随访确诊为复发和转移的病灶为165个, 另15个病灶为淋巴结反应性增生; 18F-FDG PET-CT真阳性51例、假阳性1例、假阴性4例、真阴性9例, 18F-FDG PET-CT对卵巢癌患者检出的灵敏度、特异度、准确率、阳性预测值和阴性预测值分别为92.7%(51/55)、90.0%(9/10)、93.8%(61/65)、98.1%(51/52)、69.2%(9/13)。糖类抗原125(CA125)水平与18F-FDG PET结果有较高的相关性, 47例患者的CA125升高, 其中, 44例患者PET-CT阳性, PET-CT阳性率为93.6%。 结论 PET-CT全身显像在检测卵巢癌术后复发和转移病灶方面具有较高的灵敏度和准确率, 能够使卵巢癌术后再次分期更准确、更全面。同时, CA125升高时, PET-CT全身检查在发现隐匿及远处转移病灶方面具有明显优势, 可为临床进一步诊治提供依据。 -
关键词:
- 卵巢肿瘤 /
- 肿瘤复发, 局部 /
- 肿瘤转移 /
- 氟脱氧葡糖糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术, X线计算机
Abstract:Objective To investigate the value of 18F-FDG PET-CT in the detection and diagnosis of recurrent and metastasis ovarian cancer. Methods Retrospective analysis of whole body PET-CT imaging data of 65 patients after operation for ovarian cancer. All the case were followed-up for 3-57 months. The diagnosis was confirmed by surgical pathological examination, imaging studies and clinical follow-up. Results Of the 65 patients, 55 cases developed tumor recurrence and metastasis, and 10 patients didn't show tumor recurrence and transfer. Of the 180 positive lesions displayed on 18F-FDG PET-CT images, 165 lesions were finally diagnosed as recurrence and metastasis, the remaining 15 lesions were identified as lymph node reactive hyperplasia. With 18F-FDG PET-CT, the accurate diagnosis were given in 60 patients(positive in 51 cases and negative in 9 cases), 1 given false positive diagnosis, and 4 cases of false negative diagnosis. As a result, the sensitivity, specificity, accuracy, positive-predictive value and negative-predictive value for detecting the ovarian lesions by 18F-FDG PET-CT were 92.7%(51/55), 90.0%(9/10), 93.8%(61/65), 98.1%(51/52), 69.2%(9/13)respectively. Carbohydrate antigen 125(CA125)levels had a positive relationships with the results of 18F-FDG PET-CT. The level of CA125 was increased in 47 cases, and positive images were found in 45 cases, the positive rate was 95.7%. Conclusion 18F-FDG PET-CT has a high sensitivity and accuracy in the detection of recurrent and metastasis ovarian cancer. It is recommend to perform 18F-FDG PET-CT, in particular when elevated CA125 is detected. -
[1] Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics, 2011, 31(2):569-583. doi: 10.1148/rg.312105713 [2] Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma:the Gynecologic Oncology Group experience. J Clin Oncol, 1991, 9(7):1138-1150. doi: 10.1200/JCO.1991.9.7.1138 [3] 吴湖炳, 王全师, 王明芳, 等. PET/CT显像在探查卵巢癌术后复发、转移中的应用.中华核医学杂志, 2006, 26(4):197-200. doi: 10.3760/cma.j.issn.2095-2848.2006.04.001
[4] Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005, 97(1):183-191. [5] Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer:correlation with histologic findings. Radiology, 2004, 233(2):433-440. [6] 赵军, 管一晖, 左传涛, 等. 18F-FDG PET/CT在探测卵巢癌术后复发和转移中的价值.中国肿瘤, 2007, 16(3):187-189. doi: 10.3969/j.issn.1004-0242.2007.03.012
[7] Rubini G, Altini C, Notaristefano A, et al. Peritoneal carcinomatosis from ovarian cancer:role of 18F-FDG-PET/CT and CA125. Recenti Prog Med, 2012, 103(11):510-514. [8] Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol, 2012, 14(1):123-129.